CAR T-cell therapies are often lauded as one of the industry’s most important frontiers, and these therapies have seen amazing success in treating hematological cancers — will autoimmune diseases yield next?
Seer's Proteograph Product and Analysis suites are utilizing proprietary nanoparticle technology to help us understand diseases like never before. David Horn, President and CFO, tells us more.
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
The CEO of Cellares sits down to tell us how the Cell Shuttle, an engineering marvel of 21st Century biotech, was invented and the lives that it could save...
We spoke with Stephen Gillett, Alphabet’s health-tech boss on life, leadership and AI.
Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.
Kendalle Burlin O’Connell tells us about the privilege of heading up MassBio - the organization that represents the extraordinary life sciences sector in Massachusetts.
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.
Alec Ford explains how the Karius Test® uses cutting-edge genomics to detect infections caused by more than 1,000 pathogens within a day of receiving a blood sample, offering a breakthrough for immunocompromised patients, particularly those with cancer.
Julie Ross took the helm of Advanced Clinical over a decade ago. Now, they are one of the largest private CROs in America, and have helped biotechs and pharma in 54 countries take their life-saving drugs from concept to clinic.
AI and drug discovery are multi-billion dollar markets, but money (and data) is wasted every year from a poor understanding and implementation of translatability from animal models to humans. Dr. Jo Varshney's BIOiSIM platform seeks to change that.
There is a huge boom in the newfound 'GLP-1 supplements' industry, and New Zealander CaloCurb is taking advantage, seeing 400% to 600% growth per quarter. They are now in the middle of their fourth, and largest, human trial - but will strong clinical results be enough to capture the market?
It took little over 40 Opentrons robots to provide the majority of COVID-19 testing for the city of New York - 15 million people. Top-tier investors have piled in, will their bets pay off in 2025?
Lexicon has been discovering new genetic science since the Human Genome Project. They've retained investor interest, and have 2 solid new FDA approvals. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this Summer and has plans to make history... in 2025 Lexicon is
